Newsroom

Immunotherapy against hepatitis B
News
Hepatitis B is a viral infection of the liver that can lead to cancer and organ failure. Antiviral therapies can suppress the infection, but a functional cure is rare. Novel immunotherapies may lead to an actual cure more often. However, it is still unclear which patients benefit most from these new therapies. Researchers at the Centre for Individualised Infection Medicine (CiiM), a joint institution of the Helmholtz Centre for Infection Research (HZI) and the Hannover Medical School (MHH), as well as the MHH and the German Center for Infection Research (DZIF), have now identified a biomarker that intends to enable predictions about the success of the therapy. The results were published in the scientific journal Gut.
25.11.2021
Infection and immunity week
News
The Helmholtz Centre for Infection Research (HZI) in Braunschweig and the McGill Interdisciplinary Initiative in Infection and Immunity (MI4) at McGill University in Montréal, Canada, are organising a joint symposium on personalised infection medicine on 29 November. Three researchers from each of the two institutions will give lectures on various topics of personalised infection medicine. The keynote lecture will be given by Prof Ugur Sahin, co-founder and CEO of BioNTech SE. The symposium kicks off McGill University's “Infection and Immunity Week”, which celebrates its 200th anniversary this year. Interested scientists can register to follow the event online.
23.11.2021
Filterplättchen
News
Ahead of the “World Antimicrobial Awareness Week” (November 18-24) 20 national and international organizations from academia, healthcare and the pharmaceutical industry appealed today to G7 governments to step up efforts to tackle the problem of growing antibiotic resistance. Their "Joint Statement on Strengthening the Antibiotic R&D Pipeline by Rewarding Innovation" stresses that only an approach involving both the public and private sectors is likely to succeed. The Helmholtz Centre for Infection Research (HZI) is a member of the Helmholtz Association of German Research Centres and the German Center for Infection Research (DZIF), which both signed the statement.
17.11.2021
 Aktin-Zytoskelett in Maus-Melanomzellen
News
Researchers from the Helmholtz Centre for Infection Research (HZI) and partners from the University of Bordeaux have established a mechanism that regulates the migration of individual cells. The study was recently published in Nature Cell Biology and discussed in an accompanying article by renowned experts.
16.11.2021
Illustration von antiviralen Wirkstoffen
News
The Federal Agency for Disruptive Innovation (SPRIND) has announced the participants of the first SPRIND Challenge “A Quantum Leap for New Antiviral Agents”. From 45 applications from Germany and Europe, the jury selected a total of nine teams. Prof Mark Brönstrup from the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Prof Chase Beisel from the Helmholtz Institute for RNA-based Infection Research (HIRI), a joint institution of the HZI with the Julius-Maximilians-Universität Würzburg (JMU), convinced the jury with the projects they led. The HZI scientists Prof Carlos A. Guzmán and Dr Christian Sieben are involved in two other projects as cooperation partners. The teams will each receive up to 700,000 euros in the first year of the three-year competition to develop new drug candidates against viral diseases.
10.11.2021

HZI in the media

new antiviral medicines, says virologist Christian Sieben of the Helmholtz Centre for Infection Research in Germany.

 

Earlier in 2025, for

10.11.2025
|
The Press

Hochschule Hannover, die Universitätsmedizin Göttingen, das Helmholtz-Zentrum für Infektionsforschung in Braunschweig sowie die KI-

07.11.2025
|
Heise online

... , Leiter der Forschungsgruppe Mikrobielle Wirkstoffe am Helmholtz-Zentrum für Infektionsforschung, zu bedenken. Das erste ...

07.11.2025
|
Leipziger Volkszeitung (LVZ)

Quelle: Pressemitteilung

 

HZI-Helmholtz Zentrum für Infektionsforschung ...

04.11.2025
|
LaborPraxis

Forschende des Helmholtz-Zentrums für Infektionsforschung und der Universität Würzburg entwickeln derzeit einen Kaugummi, der Grippeviren

04.11.2025
|
Arbeitsmedizin-Sozialmedizin-Umweltmedizin

... Vakzinologie und angewandte Mikrobiologie am Helmholtz-Zentrum für Infektionsforschung. Die M2-Membranproteinhemmer verhindern ...

02.11.2025
|
Augsburger Allgemeine

... etwas dran ist“, erklärt Biologe Marc Stadler vom Helmholtz-Zentrum für Infektionsforschung gegenüber der Barmer-Krankenkasse. „Es ...

30.10.2025
|
bild der wissenschaft

could be reintroduced at any time. Epidemiologists at the Helmholtz Center for Infection Research (HZI) have now shown that many people do

23.10.2025
|
MSN.com

... eingeschleppt werden könnte. Epidemiolog:innen des Helmholtz-Zentrums für Infektionsforschung (HZI) haben nun gezeigt, dass ...

23.10.2025
|
innovations report

this development, a research team at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in collaboration with the Swiss

22.10.2025
|
Phys.org

Malaria-Medikamentes ermöglichen könnte. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung in Zusammenarbeit mit ...

22.10.2025
|
Verband Deutscher Biologen e.V.

(Bild: DOI: 10.1021/jacs.5c08354 / Hips / CC BY 4.0) Wissenschaftler am Hips entwickelten eine Plattform zur Produktion von Furanoliden, die effektiv gegen Bakterien und Krebszellen wirken können und vielversprechende Wirkstoffe darstellen.

21.10.2025
|
PROCESS

Register now for the HZI-Newsletter